Navid Malik, The Life Sciences Division, talks to Andrew Scott at Proactive about ImmuPharma’s licencing deal with Avion and how it has re-ignited the potential for Lupuzor to be a blockbuster drug – 16 December 2019

16th December 2019 - 12:42 pm

The Life Sciences Division’s Navid Malik gives his view on the recent recent deal ImmuPharma PLC (LON:IMM) struck with US speciality drugs group Avion Pharmaceuticals.

Share this article